Cargando…

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma

BACKGROUND: Leptomeningeal disease (LMD) is a devastating complication of systemic malignancy, portending a poor prognosis with an estimated median survival of 4–6 weeks if left untreated. Several reports have suggested surgical resection, particularly piecemeal resection, as a potential causative f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lowe, Stephen, Wang, Christopher P, Brisco, Amanda, Ahmed, Kamran, Vogelbaum, Michael A, Liu, James K C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351301/ http://dx.doi.org/10.1093/noajnl/vdab071.044

Ejemplares similares

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease
por: Najem, Hinda, et al.
Publicado: (2021)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023)

BSCI-01 INTRATHECAL DELIVERY OF DENDRITIC CELL VACCINE ERADICATES TUMOR GROWTH AND PROTECTS AGAINST LEPTOMENINGEAL DISEASE (LMD) RE-INOCULATION IN IMMUNOCOMPETENT HER2+ AND TRIPLE NEGATIVE BREAST CANCER (TNBC) LMD XENOGRAFT MODELS
por: Law, Vincent, et al.
Publicado: (2022)

LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Brenner, Andrew, et al.
Publicado: (2021)

LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report
por: Wang, Hui, et al.
Publicado: (2021)

LMD-15. Beyond cytologY - A single institution experience using CNSide(TM) for diagnosing and monitoring treatment response in Non-Small Cell Lung Cancer patients with Leptomeningeal Carcinomatosis (LMC)
por: Akerley, Wallace, et al.
Publicado: (2021)

LMD-01. Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
por: McThenia, Sheila, et al.
Publicado: (2021)

LMD-11. Pure spinal cord invasion in recurrent classic Hodgkin’s Lymphoma - what is it?
por: Awori, Violet, et al.
Publicado: (2021)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022)

LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival
por: Smalley, Inna, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

Metastatic Melanoma With Leptomeningeal Disease
por: Marinova, Amanda M., et al.
Publicado: (2021)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

LOCL-06 SUPERVISED MACHINE LEARNING IDENTIFIES RISK FACTORS ASSOCIATED WITH LEPTOMENINGEAL DISEASE AFTER SURGICAL RESECTION OF BRAIN METASTASES
por: Morshed, Ramin, et al.
Publicado: (2022)

41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS
por: Le Rhun, Emilie, et al.
Publicado: (2020)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS
por: Henry, Katie, et al.
Publicado: (2022)

SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023)

21. A PHASE II TRIAL OF COMPREHENSIVE TREATMENT BASED ON RADIOTHERAPY IN LEPTOMENINGEAL METASTASIS
por: Yang, Siran, et al.
Publicado: (2020)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
por: Jiang, Wulin, et al.
Publicado: (2020)

11. ASSOCIATION OF TUMOR EXPOSURE TO CEREBROSPINAL FLUID SPACES TO LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES
por: Patel, Kunal, et al.
Publicado: (2020)

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN- 2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS
por: Chi, Yudan, et al.
Publicado: (2021)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era
por: Chen, Kuan-Yu, et al.
Publicado: (2021)

Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review
por: Wallace, Gerald, et al.
Publicado: (2023)

58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
por: Eastman, Boryana, et al.
Publicado: (2020)

12. OUTCOMES AFTER SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE AGE OF CHECKPOINT INHIBITOR TREATMENT
por: Morshed, Ramin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_61om7j2tme3oq4v7rftse1l9c1